Pediatrics
Showing 41-50 of 73 Results
-
Maya Mathur
Associate Professor (Research) of Pediatrics, of Medicine (Computational Medicine) and, by courtesy, of Epidemiology and Population Health
On Partial Leave from 05/01/2026 To 06/30/2026Current Research and Scholarly InterestsSynthesizing evidence across studies while accounting for biases
-
Mark McGovern
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences) and, by courtesy, of Pediatrics
BioDr. Mark McGovern is a Professor and the Associate Chair of Translation and Implementation Research in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine.
Most people who need health care do not receive it. And of those who do, wide variation exists in access to care and the quality of the care they receive in health care systems, both private and public. Dr. McGovern is a leader in using rigorous methods of implementation science to close these gaps in health care delivery.
His mission is to get the best health care possible to the people who need it the most.
Dr. McGovern's primary focus is the implementation and sustainment of evidence-based interventions and guideline adherent care in public and private health care systems and organizations. Within the hub of the Stanford Center for Dissemination and Implementation (CDI) which he directs, Dr. McGovern is the Principal Investigator (PI) and leads three national implementation research and practice centers: The Center for Dissemination and Implementation At Stanford (C-DIAS); The Research Adoption Support Center (RASC); and, the Mental Health Technology Transfer Center Network Coordinating Center (MHTTC). The 3 centers are federally-funded, respectively by the National Institute on Drug Abuse (P50DA05402), the National Institutes of Health Healing Addiction Long Term (HEAL) initiative (U2CDA057717), and the US Department of Health and Human Services Substance Use and Mental Health Services Administration (H79SM081726). Dr. McGovern is also the PI on a multi-site adaptive implementation trial across a state system of care, which aims to integrate addiction medications for persons with opioid use disorder who are receiving services in specialty or primary care organizations (R01DA052975). In addition, he addresses implementation challenges in federally-qualified health centers (FQHCs) across the State of California, in the Stanford Division of Primary Care and Population Health, and in specialty addiction and mental health treatment organizations nationwide. He leads, facilitates and/or actively engages networks advancing implementation science in health, including the NIDA Clinical Trials Network Translation & Implementation Special Interest Group, the NIDA Clinical Trials Western States Node Translation & Implementation Workgroup, the Stanford University Network for Dissemination & Implementation Research (SUNDIR), the VA Palo Alto HSR&D Center for Innovation to Implementation, and the Stanford Medicine Center for Improvement. He is on the Core Faculty of the National Institute of Mental Health Implementation Research Institute at the Washington University in St. Louis. Dr. McGovern is a collaborator on multiple projects as a co-investigator, consultant, or advisory board member. He is a mentor to numerous individuals across the country and at Stanford, from university undergraduates to mid-career faculty and clinical administrators at academic institutions and health care systems nationwide. -
Michelle Monje
Milan Gambhir Professor of Pediatric Neuro-Oncology and Professor, by courtesy, of Neurosurgery, of Pediatrics, of Pathology and of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsThe Monje Lab studies the molecular and cellular mechanisms of postnatal neurodevelopment. This includes microenvironmental influences on neural precursor cell fate choice in normal neurodevelopment and in disease states.
-
Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology and, by courtesy, of Pediatrics and of Medicine (Immunology & Rheumatology)
Current Research and Scholarly InterestsWe have focused our research on the development of novel therapies and innovative assessment and diagnostic imaging technologies for retinal vascular and ocular inflammatory disorders, specifically diabetic retinopathy (DR), age-related macular degeneration (AMD) and uveitis. Building on our initial work describing the role of hypoxia and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and diabetic macular edema (DME), We have become interested in the biochemical mechanisms that would presumably lead to DME. During the past decade, our research has contributed to the body of evidences that defines the important role of anti-VEGF therapies in DME and AMD, as well as the role of the mTOR pathway and various interleukins in the pathogenesis of uveitis.
We have launched a productive and well-funded clinical research program while at the same time providing clinical care to patients with uveitis and retinal vascular diseases and fulfilling significant teaching and administrative assignments. We have established a number of key collaborators both within and outside the institutions. In addition, we have also established Center in Baltimore and now in Silicon Valley, which has excelled in conducting proof-of concept, early-phase multi-center clinical trials and studies, exploring the clinical disease manifestations and the efficacy of various pharmacologic agents in retinal, uveitic, and ocular inflammatory disorders.
